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Background: The incidence of thyroid cancer is rising, and relatively little is known about 
modifiable risk factors for the condition. Observational studies have suggested a link between 
adiposity and thyroid cancer; however, these are subject to confounding and reverse causality. 
Here, we used data from the UK Biobank and Mendelian randomization approaches to 
investigate whether adiposity causes benign nodular thyroid disease and differentiated thyroid 
cancer.
Methods: We analyzed data from 379 708 unrelated participants of European ancestry in the 
UK Biobank and identified 1812 participants with benign nodular thyroid disease and 425 
with differentiated thyroid carcinoma. We tested observational associations with measures of 
adiposity and type 2 diabetes mellitus. One and 2-sample Mendelian randomization approaches 
were used to investigate causal relationships.
Results: Observationally, there were positive associations between higher body mass index 
(odds ratio [OR], 1.15; 95% confidence interval [CI], 1.08-1.22), higher waist-hip ratio (OR, 1.16; 
95% CI, 1.09-1.23), and benign nodular thyroid disease, but not thyroid cancer. Mendelian 
randomization did not support a causal link for obesity with benign nodular thyroid disease or 
thyroid cancer, although it did provide some evidence that individuals in the highest quartile for 
genetic liability of type 2 diabetes had higher odds of thyroid cancer than those in the lowest 
quartile (OR, 1.45; CI, 1.11-1.90).
Conclusions: Contrary to the findings of observational studies, our results do not confirm a 
causal role for obesity in benign nodular thyroid disease or thyroid cancer. They do, however, 
suggest a link between type 2 diabetes and thyroid cancer. (J Clin Endocrinol Metab 105: 
e2398–e2407, 2020)
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Thyroid cancer is the most common endocrine ma-lignancy, and its incidence is increasing, with rates 
expected to rise by 74% by 2035 in the United Kingdom 
(1). Along with childhood radiation exposure, a history 
of benign nodular thyroid disease is an important risk 
factor for differentiated thyroid cancer, suggesting that 
rather than representing distinct entities, benign nodules 
and thyroid cancers may fall on a spectrum of thyroid 
neoplasia (2, 3).
Among the frequently cited risk factors for malig-
nancy in a patient presenting with a thyroid nodule 
is obesity (4), which is itself a growing public health 
concern. Large pooled analyses of case control studies 
(6796 and 848  932 participants, respectively) have 
demonstrated an association between body mass index 
(BMI) and thyroid cancer risk in men and women (5, 
6), and 2 subsequent meta-analyses have corroborated 
these findings (7, 8). In addition, there is also some evi-
dence from retrospective studies that obesity is associ-
ated with more aggressive features of thyroid cancers, 
including larger tumor size, extrathyroidal extension, 
more advanced tumor stage, and persistent disease fol-
lowing treatment (9-11). However, these studies tend 
to be observational, which carries an inherent risk of 
bias because of confounding factors and reverse caus-
ality. For example, obese patients may be more likely 
to undergo thyroid function screening than the general 
population, and tend to have higher TSH levels, which 
may be an independent risk factor for thyroid cancer 
(12). Efforts have been made to remove this bias by 
measuring BMI at the time of cytological analysis in pre-
viously undiagnosed patients with thyroid nodules, and 
found no association between BMI and thyroid cancer 
(13). Further complicating the link between obesity and 
thyroid cancer is the finding that type 2 diabetes mel-
litus (T2DM), a disease strongly associated with obesity, 
has been identified as a risk factor both for increased 
TSH levels (14) and thyroid cancer (15, 16).
The use of genetic epidemiology to unravel environ-
mental determinants of disease relies on the fact that 
inheritance of genetic variants at conception is random 
and cannot be confounded by other risk factors. 
Mendelian randomization (MR; Fig. 1) uses genetic de-
terminants of a trait such as obesity to test the hypoth-
esis that the trait increases the risk of a disease (such 
as thyroid cancer) in the absence of bias from reverse 
causality and confounding (17).
Genome-wide association studies (GWAS) have iden-
tified many polymorphisms associated with obesity (18), 
which can be used to construct individual genetic risk 
scores (GRS) and perform MR. Here, we test the hy-
pothesis that obesity and other adiposity-related factors 
increase the risk of benign nodular thyroid disease and 
differentiated thyroid cancer. We used cancer registry 
data and clinical and genetic information from 379 708 
unrelated participants of European ancestry in the UK 
Biobank to perform 1-sample MR, and 451 025 partici-
pants (without exclusion of related individuals) to per-
form 2-sample MR.
Materials and Methods
Participants
The UK Biobank is a longitudinal study of 500 000 par-
ticipants between the ages of 40 and 69 recruited between 
2006 and 2010 (19). Demographic and health-related infor-
mation was obtained via questionnaires and interviews, and 
anthropometric measurements, blood pressure readings, and 
blood, urine, and saliva samples were taken at enrollment 
(20). Extensive health data are available via linkage with na-
tional cancer and death registries and the Hospital Episode 
Statistics database.
Genotyping was performed by Affymetrix (Santa Clara, 
CA) using DNA extracted from whole blood samples. Two 
specially designed single nucleotide polymorphism arrays with 
more than 95% content overlap were used: the UK Biobank 
Axiom array® was used for ~440 000 participants, and the UK 
BiLEVE Axiom array® for 50 000 participants (21). Sample 
quality control was performed by removing duplicated indi-
viduals, those identified as sex mismatches, of non-European 
descent, or outliers of heterozygosity, with an overall propor-
tion of samples identified as poor quality of 0.2% (22).
Exposure and outcome measures
To investigate the effect of obesity on the risk of developing 
benign nodular thyroid disease and thyroid cancer, a range of 
obesity-related exposure measures was used, including BMI, 
waist-hip ratio (WHR), and WHR adjusted for BMI. These 
were defined from the baseline measures, with BMI calculated 
from measured weight and height and WHR from measured 
waist and hip circumference. T2DM was also included as an 
exposure measure and was identified from the baseline ques-
tionnaire, as described previously (23). In brief, participants 
who had ever been told they had diabetes by a doctor were 
identified, then excluded if they were diagnosed under the age 
of 35, had received insulin within the first year of diagnosis, or 
were diagnosed less than a year before the date of enrollment 
Trait
(obesity)
Disease
(thyroid cancer)
Confounders
Genec risk of obesity
73 BMI SNPs
Figure 1. If a risk factor (e.g., body mass index) truly causes an 
outcome (e.g., thyroid cancer), then the genetic variants for the 
risk factor should also be associated with the outcome. Unlike the 
observed risk factor, the genetic variants are not susceptible to 
confounding by other risk factors as they are assigned at conception.
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to reduce the risk of inadvertently including participants with 
type 1 diabetes mellitus. Serum lipid levels and blood glucose 
were also used as biomarkers for metabolic health and their 
associations with benign thyroid disease and thyroid cancer 
were investigated.
Thyroid cancer cases were identified by the International 
Classification of Diseases-10 code C73 in the linked Cancer 
Registry data. Histology codes were used to refine the case 
definition. Specifically, participants were excluded if they 
had a diagnosis of medullary or anaplastic carcinoma, thy-
roid lymphoma, or unspecified histological subtypes because 
of the different etiology and pathophysiology of these sub-
types. Finally, the date of first diagnosis was used to ensure 
that duplicated records and recurrences were excluded. This 
resulted in 638 cases including related individuals (and 425 
after exclusion of related individuals). Benign nodular thyroid 
disease was defined using the International Classification of 
Diseases-10 code D34 from Hospital Episode Statistics data. 
Patients with toxic nodules were excluded. This resulted in 
2149 cases, including related individuals (and 1812 after ex-
clusion of related individuals). Date of diagnosis was used to 
exclude individuals diagnosed with both benign nodular thy-
roid disease and thyroid cancer within 12 months to exclude 
cases of diagnostic uncertainty. Separate control groups were 
used for the 2 cohorts to maximize comparability and reduce 
confounding, so that controls had no history of any cancer 
(n = 310  176) and no history of nodular thyroid disease 
(n = 377 896), respectively.
Genetic data
Genetic variants for each potential risk factor were taken 
from published GWAS that excluded the UK Biobank. 
Seventy-three genetic variants associated with BMI were iden-
tified from the GIANT consortium study of up to 338 224 
individuals (24), after exclusion of those not associated 
with BMI in all people of European ancestry, those reaching 
genome-wide levels of statistical significance in only 1 sex, and 
those known to be classified as a secondary signal within a 
locus. In a similar fashion, variants for WHR, WHR adjusted 
for BMI (adjWHR) (25) and T2DM risk (26) were identified. 
Finally, 14 common genetic variants associated a high body 
fat percentage but low metabolic disease risk, as identified by 
Yaghotkar et al (27) were used as favorable adiposity variants. 
Weighted GRS for each potential risk factor trait were pro-
duced using the size of the effect of each variant as reported in 
the primary GWAS and rescaled according to the number of 
trait-causing alleles. All genetic risk scores strongly associated 
with their corresponding traits, with all F statistics >10.
Statistical analysis of observational data
Initial analyses using logistic regression models were per-
formed to ascertain demographic differences between cases 
and controls. We then investigated associations between clin-
ical measures of obesity and related metabolic parameters 
(including serum high-density lipoprotein [HDL], low-density 
lipoprotein [LDL], triglycerides, and glucose), and thyroid 
cancer and benign nodular thyroid disease using logistic re-
gression models. These models included age, sex, smoking 
status, alcohol consumption, Townsend deprivation index, 
BMI, and T2DM as covariates. Only factors found to be as-
sociated with either benign nodular thyroid disease or thyroid 
cancer in these observational analyses were taken forward for 
Mendelian randomization as outlined below.
Statistical analysis of genetic data
MR (Fig. 1) uses genetic variants as instrumental variables, 
which are associated with an outcome only through their 
association with a particular risk factor (for example, meas-
ured BMI) (28). MR relies upon three assumptions: first, that 
the instrumental variable is associated with the risk factor of 
interest; second, that the instrumental variable is not affected 
by the confounding factors acting upon the association be-
tween the risk factor and outcome of interest; and, finally, that 
the instrumental variable is associated with the outcome of 
interest only via its effect on the modifiable risk factor.
One-sample MR was performed in 2 stages using the GRS. 
First, the strength of the instrumental variables was tested 
by regressing against the corresponding observed risk fac-
tors, using linear regression for continuous predictors and 
logistic regression for binary predictors, with adjustment for 
age, sex, assessment center, ancestral principal components, 
and genotyping platform. Predicted values and residuals from 
this regression model were saved (representing unconfounded 
estimates of variation in observed variants) and used in the 
second stage as the independent variable, with disease status 
as the dependent variable. Robust standard errors were used 
to allow for uncertainty in the estimate. Sensitivity analysis 
was performed by excluding patients with a background of 
hypothyroidism or hyperthyroidism (Table 1).
Two-sample MR was also performed in a larger related 
subsample (n = 451 025). Here, GWAS of the thyroid cancer 
and benign nodular thyroid disease variables were performed 
using BOLT-LMM software to correct for inter-relatedness 
(29). Known genetic variants for our predictor traits of interest 
were then extracted and 3 different methods of 2-sample MR 
performed. First, inverse variant weighted instrumental vari-
able analysis. Inverse variant weighted assumes that all genetic 
instruments are valid and is therefore susceptible to horizontal 
pleiotropy whereby variants have an effect on the outcome via 
a route other than the risk factor of interest. To reduce this po-
tential source of bias, we also used the MR-Egger and Median 
MR techniques (30, 31), which are more robust to pleiotropy. 
In MR-Egger analysis, the intercept is unconstrained to re-
move the assumption that all variants are valid instrumental 
variables and allow a weighted regression. This reduces the 
possibility of variants having a stronger effect on the outcome 
than the exposure trait. Median-MR uses the median instru-
mental variable from all included variants and allows for up 
to 50% of the variants to be invalid, and thus is also more 
resistant to pleiotropy.
Results
Basic demographic information on included partici-
pants and controls is displayed in Table 2. Participants 
in both the benign nodular thyroid disease and thy-
roid cancer groups were more likely to be female and 
older at recruitment than controls. Other demographics 
including smoking status, Townsend Deprivation Index, 
alcohol intake, mean BMI, and WHR were not different 
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between the thyroid cancer and control groups. There 
were, however, differences in the benign nodular thyroid 
disease group, with cases more likely to be obese, more 
likely to have T2DM, less likely to be current smokers, 
have a lower alcohol intake, be more deprived (based 
on the Townsend Deprivation Index), and have a lower 
WHR. Of the 425 patients with a diagnosis of differ-
entiated thyroid cancer, 117 had a previous history of 
benign nodular thyroid disease.
Observational associations
Benign nodular thyroid disease.  Higher adiposity 
was associated with a higher odds of benign nodular 
thyroid disease, for example obese patients (defined 
by a BMI between 30 and 40  kg/m2) had a 1.38 
higher odds (95% confidence interval [CI], 1.17-1.62) 
than those with a normal BMI, and each 1 standard 
deviation increase in BMI (4.8  kg/m2) resulted in a 
1.15 higher odds of benign nodular thyroid disease 
(95% CI, 1.08-1.22). WHR and adjWHR were asso-
ciated with benign nodular thyroid disease, although 
some sex differences were observed, with stronger as-
sociations in men than in women (Tables  3 and 4). 
T2DM was not associated with benign nodular thy-
roid disease (Table 3).
Measured serum HDL and LDL levels were both as-
sociated with a lower odds of benign nodular thyroid 
disease; however, there was no association with serum 
triglycerides or glucose levels (Table 3).
Thyroid cancer.  Obesity was trending toward 
higher odds of thyroid cancer (odds ratio [OR], 1.34; 
95% CI, 0.99-1.84), as was higher WHR (OR, 1.12; 
95% CI, 1.00-1.26) and adjWHR (OR, 1.13; 95% 
Table 2. Summary of Demographic Characteristics of Included Participants
Characteristic
Benign  
Nodular  
Thyroid  
Disease Controls P Value
Thyroid  
Cancer
Cancer-free 
Controls P Value
N 1812 377 896  425 310 176  
Female 1492 (82.34) 203 244 (53.78) <1 × 10-15 316 (74.35) 165 537 (53.37) 5.6 × 10-17
Mean age at recruitment  
(SD), years
58.92 (7.39) 57.23 (8.01) <1 × 10-15 57.72 (7.29) 56.54 (8.04) 0.0022
Smoking status       
Never 976 (53.86) 203 242 (53.78) 0.04 233 (54.82) 169 785 (54.74) 0.40
Former 649 (35.82) 133 744 (35.40) 152 (35.76) 107 027 (34.51)
Current 166 (9.16) 35 774 (9.47) 32 (7.53) 29 261 (9.43)
Missing 21 (1.16) 5136 (1.36) 8 (1.88) 4103 (1.32)
Mean Townsend Deprivation  
index (SD)
-1.16 (3.09) -1.48 (2.99) 4.8 × 10-8 -1.63 (2.94) -1.45 (2.99) 0.42
Inverse normalized mean units  
of alcohol per week (SD)
0.20 (1.07) 0.57 (1.04) 2.5 × 10-6 0.37 (1.00) 0.57 (1.04) 0.48
Mean BMI (SD), kg/m2 27.96 (5.23) 27.38 (4.78) 4.1 × 10-12 27.55 (5.34) 27.38 (4.77) 0.16
Obese: BMI 30-40 kg/m2 471 (25.99) 83 503 (22.10) 1.6 × 10-9 111 (26.12) 68 563 (22.10) 0.068
Mean waist hip ratio (SD) 0.85 (0.087) 0.87 (0.090) 1.4 × 10-9 0.85 (0.90) 0.87 (0.09) 0.083
Type 2 diabetes 70 (3.86) 11 996 (3.17) 0.0037 16 (3.76) 9290 (3.0) 0.16
Values stated are numbers (percentages), unless otherwise stated. P values calculated using logistic regression adjusted for age and sex.
BMI, body mass index; SD, standard deviation.
Table 1. Sensitivity Analysis for 1-sample MR with Exclusion of Patients with a Diagnosis of Hyperthyroidism 
or Hypothyroidism
Analysis Exposure OR Thyroid Cancer 95% CI OR Benign Nodular Thyroid Disease 95% CI
Primary analysis BMI 1.18 0.55-2.52 0.87 0.61-1.25
WHR 1.45 0.55-3.85 1.52 0.93-2.50
adjWHR 0.80 0.53-1.21 1.07 0.86-1.32
T2DM 1.22 0.89-1.69 0.99 0.84-1.16
FA 0.99 0.95-1.03 1.01 0.98-1.08
Sensitivity analysis BMI 1.18 0.55-2.52 0.86 0.60-1.22
WHR 1.45 0.55-3.85 1.55 0.94-2.54
adjWHR 0.79 0.52-1.19 1.06 0.86-1.32
T2DM 1.23 0.98-1.70 0.99 0.84-1.16
FA 0.99 0.95-1.09 1.01 0.99-1.04
adjWHR, WHR adjusted for BMI; BMI, body mass index; CI, confidence interval; FA, favourable adiposity; OR, odds ratio; T2DM, type 2 diabetes mel-
litus; WHR, waist-hip ratio.
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CI, 1.00-1.27; Table  3), but in all individuals a per 
unit higher BMI was not associated with thyroid 
cancer. There was no association between T2DM and 
thyroid cancer.
As in benign nodular thyroid disease, a higher serum 
HDL level was trending toward a lower odds of thyroid 
cancer, with each 1 standard deviation (0.38 mmol/L) 
higher HDL associating with 0.68 lower odds of thyroid 
cancer (95% CI, 0.45-1.00). LDL, triglyceride levels, 
and serum glucose were not associated with thyroid 
cancer (Table 3).
Mendelian randomization
Benign nodular thyroid disease.  There was some 
evidence that a higher genetic liability to T2DM caused 
benign thyroid disease (OR, 1.11; 95% CI, 1.01-1.21; 
Fig.  2 and Table  5). The effect estimate was con-
sistent across the more pleiotropy-resistant methods, 
Table 3. Observational Associations Between Measured Traits and Benign Nodular Thyroid Disease and 
Thyroid Cancer
Trait
OR Benign 
Nodular Disease 95% CI P Value
OR Thyroid 
Cancer 95% CI P Value
Obesity (BMI 30-
40 kg/m2)
1.38 1.17-1.62 1.2 × 10-4 1.34 0.99-1.84 5.7 × 10-
2
BMI 1.15 1.08-1.22 8.0 × 10-6 1.02 0.91-1.15 0.72
WHR 1.16 1.09-1.23 1.8 × 10-6 1.12 1.00-1.26 5.6 × 10-
2
adjWHR 1.11 1.04-1.18 8.8 × 10-4 1.13 1.00-1.27 4.8 × 10-
2
T2DM 1.04 0.71-1.5 0.85 1.03 0.48-2.20 0.95
Serum HDL 0.76 0.63-0.93 7.4 × 10-3 0.68 0.45-1.00 5.3 × 10-
2
Serum LDL 0.89 0.83-0.96 1.4 × 10-3 1.00 0.87-1.15 0.97
Serum triglycerides 0.96 0.90-1.03 0.3 1.06 0.93-1.20 0.39
Serum glucose 0.97 0.90-1.05 0.46 0.97 0.83-1.14 0.75
Continuous variables are reported as odds ratio per 1 standard deviation higher predictor. P values calculated using logistic regression with age, sex, 
smoking status, alcohol consumption, Townsend deprivation index, BMI, and T2DM as covariates.
adjWHR, WHR adjusted for BMI; BMI, body mass index; CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OR, odds 
ratio; T2DM, type 2 diabetes mellitus. WHR, waist-hip ratio.
Table 4. Observational and 1-sample MR Associations Between BMI, WHR, and Type 2 Diabetes and Benign 
Nodular Thyroid Disease and Thyroid Cancer in Men and Women
Characteristic
OR Benign 
Nodular 
Disease 95% CI P Value
OR Thyroid 
Cancer 95% CI P Value
Female BMI       
  Measured 1.18 1.10-1.26 4.2 × 10-6 1.02 0.89-1.18 0.74
  1-sample MR 0.93 0.63-1.38 0.71 0.87 .036-2.09 0.75
Male BMI       
  Measured 1.06 0.92-1.21 0.42 1.02 0.82-1.27 0.87
  1-sample MR 0.80 0.34-1.88 0.6 3.13 0.73-13.43 0.12
Female WHR       
  Measured 1.14 1.07-1.22 1.2x104 1.05 0.92-1.22 0.46
  1-sample MR 1.45 0.85-2.50 0.17 1.05 0.33-3.30 0.94
Male WHR       
  Measured 1.22 1.07-1.40 3.1 × 10-3 1.30 1.05-1.62 1.7 × 10-2
  1-sample MR 1.69 0.50-5.66 0.4 3.67 0.56-24.12 0.18
Female WHR adjusted for BMI       
  Measured 1.08 1.01-1.16 2.1 × 10-2 1.04 0.91-1.20 0.57
  1-sample MR 1.00 0.79-1.26 0.97 0.74 0.45-1.20 0.22
Male WHR adjusted for BMI       
  Measured 1.20 1.06-1.37 5.6 × 10-3 1.34 1.09-1.67 6.5 × 10-3
  1-sample MR 1.36 0.80-2.29 0.25 1.04 0.46-2.33 0.93
P values calculated using logistic regression adjusted for age, with smoking status, alcohol consumption, Townsend deprivation index, BMI, and 
T2DM used as covariates for measured values.
adjWHR, WHR adjusted for BMI; BMI, body mass index; CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OR, odds 
ratio; T2DM, type 2 diabetes mellitus. WHR, waist-hip ratio.
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but the CIs crossed the null. One-sample MR was 
not performed for T2DM because of the difficulty in 
interpreting MR using binary variables. There was no 
evidence that BMI, WHR, or favorable adiposity cause 
benign nodular thyroid disease; however, in all cases 
the CIs overlapped the observational estimates (Fig. 2). 
There was tentative evidence for a causal relationship 
between genetically instrumented higher WHR ad-
justed for BMI and benign nodular thyroid disease (OR, 
1.51; 95% CI, 0.95-2.41; P = 0.085). One-sample MR 
did not reveal evidence of a causative role for HDL 
or LDL in benign nodular thyroid disease; however, it 
revealed a protective effect of serum triglycerides (TG; 
OR, 0.69; 95% CI; 0.53-0.91). Two-sample MR did 
not demonstrate any associations between biomarkers 
and benign thyroid disease.
Thyroid  cancer. MR analysis provided no evidence 
for a causal role for BMI, WHR, adjWHR, or favor-
able adiposity, according to neither raw GRS (Fig. 3; 
Table  6) nor when analyzed by quartile for GRS. 
Although conventional MR approaches did not pro-
vide evidence that a higher genetic liability for T2DM 
caused thyroid cancer, individuals in the top 25% of 
the GRS for T2DM were at higher odds of thyroid 
cancer (OR, 1.45; 95% CI, 1.11-1.90; Table 7). Using 
1- and 2-sample MR, no causative role was found for 
LDL, HDL, or TG levels.
Discussion
Principal findings
This study examined the causal role of adiposity and 
related traits in both benign nodular thyroid disease 
and thyroid cancer, and started by examining observa-
tional associations between measured traits and both 
outcomes. There was no evidence of an association 
between observed BMI and thyroid cancer among UK 
Biobank participants, although there was a positive as-
sociation between observed BMI and both WHR and 
WHR adjusted for BMI and benign nodular thyroid 
disease.
Other published observational studies have re-
ported somewhat inconsistent results regarding 
obesity and thyroid cancer. Positive associations have 
been reported by pooled analysis of retrospective co-
hort studies (4) and meta-analyses (7, 8). However, 
these analyses relied on a heterogeneous group of 
studies with varying levels of adjustment for con-
founding factors such as a previous diagnosis of be-
nign nodular thyroid disease, which is in itself a known 
risk factor for the development of thyroid cancer (3). 
Furthermore, a prospective study focusing on a group 
of patients known to have thyroid nodules measured 
their BMI at the time of cytological analysis and found 
an inverse relationship between obesity and malignant 
features on cytology, and no relationship when con-
sidering a smaller subset of patients with surgical hist-
ology available (13).
Using MR, we did not find evidence of a causal link 
between obesity and benign nodular thyroid disease to 
support our observational findings. This could be due to 
confounding factors such as T2DM or TSH levels that 
increase both the risk of benign nodular thyroid disease 
and obesity, resulting in false associations when using 
clinical observations, which are limited by using gen-
etic variants. In addition to this, the MR findings do not 
support a causal role for obesity in thyroid cancer.
MR provided some evidence for a causal link be-
tween T2DM and benign nodular thyroid disease, 
which supports the observational association in the UK 
Biobank. Although there was no observational associ-
ation between T2DM and thyroid cancer, the patients 
in the top quartile for genetic risk of T2DM did have a 
significantly higher odds of thyroid cancer, suggesting a 
possible causative role.
Previous observational studies investigating the link 
between T2DM and thyroid cancer have identified a 
positive association (15, 16). This along with the nega-
tive findings for obesity-related risk factors suggests 
that type 2 diabetes may be a risk factor for thyroid 
cancer independent of obesity. The mechanisms for this 
0.0 0.5 1.0 1.5 2.0 2.5
Odds of benign nodular thyroid disease
T2DM
FA
adjWHR
WHR
BMI
Observed
1−sample MR
2−sample MR
Figure 2. Forest plot showing observed, 1 sample MR and 2 sample 
MR (instrumental variable analysis) associations between BMI, WHR, 
adjWHR, favorable adiposity, T2DM, and benign nodular thyroid 
disease. Odds ratios and 95% confidence intervals are shown (there 
are no observational estimates for favorable adiposity because this 
phenotype of higher adiposity and lower risk of metabolic disease can 
only be tested in this context with genetic variants. One-sample MR 
was not performed for T2DM because of the difficulty interpreting 
results using binary variables). adjWHR, WHR adjusted for BMI; BMI, 
body mass index; MR, Mendelian randomization; T2DM, type 2 
diabetes mellitus; WHR, waist-hip ratio.
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association are not clear; however, IGF-1 receptors are 
overexpressed on thyroid cancer cells and may be ac-
tivated by chronically elevated levels of circulating in-
sulin, leading to cell proliferation (16). This theory is 
supported by the finding that thyroid nodules are asso-
ciated with insulin resistance (32). Further work is re-
quired to confirm the causal role of T2DM; however, 
if confirmed, it could have implications for risk strati-
fication and management of indeterminate nodules in 
diabetic patients.
We also investigated the association between serum 
lipid levels and both benign nodular thyroid disease and 
thyroid cancer, using observed levels as well as genet-
ically instrumented levels. We found measured HDL 
and LDL to be inversely associated with odds of benign 
nodular thyroid disease; however, the findings of the 
MR analysis suggested no association between either 
HDL or LDL and benign nodular thyroid disease or 
thyroid cancer. MR did however suggest an unexpected 
protective role for higher TG levels in benign nodular 
thyroid disease but not thyroid cancer. This association 
needs further validation.
Strengths and limitations
This represents the first MR study on the effect of 
adiposity and related traits on nodular thyroid disease 
and thyroid cancer; however, we acknowledge some Ta
b
le
 5
. 
R
es
u
lt
s 
o
f 
2-
sa
m
p
le
 M
R
 A
n
al
ys
is
 f
o
r 
B
en
ig
n
 N
o
d
u
la
r 
Th
yr
o
id
 D
is
ea
se
Tr
ai
t
 IV
W
Eg
g
er
W
M
PW
M
O
R
 (
95
%
 C
I)
P 
Va
lu
e
O
R
 (
95
%
 C
I)
P 
V
al
u
e
In
t 
p
O
R
 (
95
%
 C
I)
P 
V
al
u
e
O
R
 (
95
%
 C
I)
P 
V
al
u
e
BM
I
1.
10
 (0
.8
2-
1.
50
)
0.
51
0.
59
 (0
.3
1-
1.
12
)
0.
11
0.
03
0.
67
 (0
.4
3-
1.
01
)
0.
07
0.
67
 (0
.4
3-
1.
04
)
0.
08
W
H
R
0.
95
 (0
.7
2-
1.
24
)
0.
69
1.
06
 (0
.4
8-
2.
33
)
0.
89
0.
76
0.
90
 (0
.6
1-
1.
33
)
0.
59
0.
90
 (0
.6
0-
1.
34
)
0.
60
W
H
R 
ad
ju
st
ed
 f
or
 
BM
I
1.
52
 (0
.9
5-
2.
41
)
0.
08
0.
54
 (0
.1
1-
2.
60
)
0.
45
0.
18
1.
06
 (0
.6
2-
1.
83
)
0.
83
1.
06
 (0
.6
3-
1.
80
)
0.
82
Fa
vo
ra
bl
e 
ad
ip
os
ity
0.
45
 (0
.1
5-
1.
32
)
0.
17
0.
02
 (0
.0
0-
0.
32
)
0.
02
0.
04
0.
43
 (0
.1
3-
1.
46
)
0.
18
0.
42
 (0
.1
2-
1.
52
)
0.
19
T2
D
M
1.
11
 (1
.0
1-
2.
21
)
0.
02
1.
12
 (0
.9
5-
1.
33
)
0.
17
0.
84
1.
11
 (0
.9
7-
1.
26
)
0.
12
1.
11
 (0
.9
8-
1.
27
)
0.
11
O
dd
s 
ra
tio
s,
 9
5%
 C
Is
, a
nd
 P
 v
al
ue
s 
fo
r 
th
e 
in
ve
rs
e 
va
ria
nt
 w
ei
gh
te
d 
(IV
W
), 
Eg
ge
r, 
w
ei
gh
te
d 
m
ed
ia
n 
(W
M
), 
an
d 
pe
na
liz
ed
 w
ei
gh
te
d 
m
ed
ia
n 
(P
W
M
) a
na
ly
se
s 
ar
e 
di
sp
la
ye
d.
 In
t 
P 
re
pr
es
en
ts
 t
he
 p
 in
te
rc
ep
t 
of
 E
gg
er
 a
na
ly
si
s,
 w
hi
ch
 is
 a
 m
ea
su
re
 o
f 
ho
riz
on
ta
l p
le
io
tr
op
y.
BM
I, 
bo
dy
 m
as
s 
in
de
x;
 C
I, 
co
nfi
de
nc
e 
in
te
rv
al
; W
H
R,
 w
ai
st
-h
ip
 r
at
io
.
0 1 2 3 4
Odds of thyroid cancer
T2DM
FA
adjWHR
WHR
BMI
Observed
1−sample MR
2−sample MR
Figure 3. Forest plot showing observed, 1 sample MR and 2 sample 
MR (instrumental variable analysis) associations between BMI, WHR, 
adjWHR, favorable adiposity, T2DM, and thyroid cancer. Odds ratios 
and 95% confidence intervals are shown (there are no observational 
estimates for favorable adiposity because this phenotype of higher 
adiposity and lower risk of metabolic disease can only be tested in 
this context with genetic variants. One-sample MR was not performed 
for T2DM because of the difficulty interpreting results using binary 
variables). adjWHR, WHR adjusted for BMI; BMI, body mass index; 
MR, Mendelian randomization; T2DM, type 2 diabetes mellitus; WHR, 
waist-hip ratio.
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limitations to our approach. First, we only had 425 
thyroid cancer cases, which limits our power for both 
observational and MR analyses. The usefulness of ob-
servational analysis in particular is inevitably limited 
despite adjustment for known confounders in the stat-
istical approach, which is why MR using genetic vari-
ables was used to further explore causal associations. 
Second, the UK Biobank is not population representa-
tive because participants were limited to adults between 
the ages of 40 and 69 living in the United Kingdom, 
with some evidence of healthy volunteer bias, resulting 
in lower rates of obesity and cancer incidence than 
age- and sex-matched members of the general popu-
lation (33). Third, our definition of T2DM was based 
on self-reported T2DM, which is susceptible to recall 
bias. Although participants recently started on insulin, 
or diagnosed when younger than age 35 years were ex-
cluded to remove those with type 1 diabetes, it is in-
evitable that this approach will have resulted in the 
unnecessary exclusion of some participants with T2DM 
and perhaps the inclusion of a small number of par-
ticipants with type 1 diabetes who were diagnosed at 
older than age 35 and who were not treated with in-
sulin within a year of that diagnosis. Fourth, although 
we performed sensitivity analysis excluding patients 
with a diagnosis of hypothyroidism or hyperthyroidism, 
the diagnosis of benign nodular thyroid disease covers 
a wide range of conditions from single nontoxic nodule 
to multinodular goiter. Fifth, identification of diagnoses 
in biobanks relies upon accurate coding. Cancer registry 
coding is robust in the United Kingdom; however, coding 
of benign thyroid nodules is likely to be more spor-
adic, so our results are likely to underrepresent benign 
nodular thyroid disease within the UK Biobank popu-
lation. Similarly, identification of controls relied on the 
lack of a record of the outcomes of interest in the cancer 
registry or HES registry rather than full clinical and 
radiological examination excluding them, which means 
that some participants with thyroid cancer or benign 
nodules will undoubtedly have been included in the con-
trol groups. It is reported that the prevalence of thyroid 
nodules on neck palpation is between 2% and 6%, and 
much higher on ultrasound (34). That the prevalence of 
benign thyroid nodules in the current study population 
was around 0.5% suggests that there was a significant 
number of participants with undiagnosed nodules. As 
in all biobank research, this results in a source of detec-
tion bias for control groups. The inadvertent inclusion 
of undiagnosed cases in the control group may weaken 
the associations identified both on observational ana-
lysis and MR analysis, thus disguising the true magni-
tude of the associations. Finally, the BMI GRS we used 
has been shown previously to be associated not only T
ab
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with BMI at enrollment in the UK Biobank, but also 
with self-reported obesity at the age of 10 (27). Other 
authors have suggested that body shape in middle age 
is a more important risk factor for thyroid cancer than 
body shape in early adulthood (35). The advantage 
of our BMI GRS is that it predicts high BMI over an 
individual’s lifetime, as opposed to the 1-time measure-
ments used in many observational studies; however, the 
disadvantage is that it cannot discriminate causal effects 
of obesity at a particular time in life.
Conclusions
The incidence of thyroid cancer is increasing and there 
is limited evidence for modifiable risk factors. Obesity 
and T2DM are both reported by observational studies 
as being risk factors, and although we were able to dem-
onstrate evidence of a causative role for T2DM using 
MR, we were unable to find a causative link between 
obesity and either benign nodular thyroid disease or 
thyroid cancer. This suggests the possibility of other 
factors confounding the reported observational associ-
ations in the case of obesity. More work is needed to im-
prove our understanding of the underlying mechanisms 
for the associations between thyroid nodules, thyroid 
cancer, and obesity.
Acknowledgments
Financial Support: This work was conducted using the UK 
Biobank Resource under application number 9072. J.T. is sup-
ported by an Academy of Medical Sciences (AMS) Springboard 
award, which is supported by the AMS, the Wellcome Trust, 
GCRF, the Government Department of Business, Energy and 
Industrial strategy, the British Heart Foundation and Diabetes 
UK (SBF004\1079). R.N.B. is supported by a Wellcome Trust 
and Royal Society grant (WT104150).
Additional Information
Correspondence and Reprint Requests: Jonathan Mark 
Fussey, MBChB, Royal Devon and Exeter Hospital, Barrack 
Road, Exeter EX2 5DW, United Kingdom. E-mail: jfussey@
nhs.net.
Disclosure Summary:  The authors have no conflicts of 
interest to declare.
Data Availability: Restrictions apply to the availability of 
data generated or analyzed during this study to preserve pa-
tient confidentiality or because they were used under license. 
The corresponding author will on request detail the restrictions 
and any conditions under which access to some data may be 
provided.
References
 1. Smittenaar  CR, Petersen  KA, Stewart  K, Moitt  N. Cancer in-
cidence and mortality projections in the UK until 2035. Br J 
Cancer. 2016;115(9):1147-1155.
 2. Franceschi S, Preston-Martin S, Dal Maso L, et al. A pooled ana-
lysis of case-control studies of thyroid cancer. IV. Benign thyroid 
diseases. Cancer Causes Control. 1999;10(6):583-595.
 3. Kitahara  CM, K  Rmendiné  Farkas  D, Jørgensen  JOL, Cronin-
Fenton D, Sørensen HT. Benign thyroid diseases and risk of thy-
roid cancer: a nationwide cohort study. J Clin Endocrinol Metab. 
2018;103(6):2216-2224.
 4. Perros P, Boelaert K, Colley S, et al.; British Thyroid Association. 
Guidelines for the management of thyroid cancer. Clin Endocrinol 
(Oxf). 2014;81(Suppl 1):1-122.
 5. Dal  Maso  L, La  Vecchia  C, Franceschi  S, et  al. A pooled ana-
lysis of thyroid cancer studies. V. Anthropometric factors. Cancer 
Causes Control. 2000;11(2):137-144.
 6. Kitahara CM, Platz EA, Freeman LE, et al. Obesity and thyroid 
cancer risk among U.S.  men and women: a pooled analysis of 
five prospective studies. Cancer Epidemiol Biomarkers Prev. 
2011;20(3):464-472.
 7. Ma J, Huang M, Wang L, Ye W, Tong Y, Wang H. Obesity and risk 
of thyroid cancer: evidence from a meta-analysis of 21 observa-
tional studies. Med Sci Monit. 2015;21:283-291.
 8. Schmid D, Ricci C, Behrens G, Leitzmann MF. Adiposity and risk 
of thyroid cancer: a systematic review and meta-analysis. Obes 
Rev. 2015;16(12):1042-1054.
 9. Choi  JS, Kim  EK, Moon  HJ, Kwak  JY. Higher body mass 
index may be a predictor of extrathyroidal extension in pa-
tients with papillary thyroid microcarcinoma. Endocrine. 
2015;48(1):264-271.
 10. Kim HJ, Kim NK, Choi JH, et al. Associations between body mass 
index and clinico-pathological characteristics of papillary thyroid 
cancer. Clin Endocrinol (Oxf). 2013;78(1):134-140.
 11. Trésallet  C, Seman  M, Tissier  F, et  al. The incidence of pap-
illary thyroid carcinoma and outcomes in operative pa-
tients according to their body mass indices. Surgery. 
2014;156(5):1145-1152.
 12. Boelaert  K, Horacek  J, Holder  RL, Watkinson  JC, 
Sheppard  MC, Franklyn  JA. Serum thyrotropin concentra-
tion as a novel predictor of malignancy in thyroid nodules 
Table 7. Odds ratios for Thyroid Cancer by Quartiles of Genetic Risk of T2DM
Quartiles
No. (%)
ORa (95% CI) PCases Controls
1 89 (20.9) 77 358 (24.9) 1.00  
2 101 (23.8) 77 529 (24.9) 1.14 (0.85-1.51) 0.38
3 106 (24.9) 77 701 (25.1) 1.19 (0.90-1.57) 0.23
4 129 (30.4) 77 588 (25.0) 1.45 (1.11-1.90) 0.0068
aOdds ratios and P values adjusted for age, sex ancestral principal component, and assessment center with a logistic regression model.
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article/105/7/e2398/5835841 by guest on 19 O
ctober 2020
doi:10.1210/clinem/dgaa250 https://academic.oup.com/jcem  e2407
investigated by fine-needle aspiration. J Clin Endocrinol Metab. 
2006;91(11):4295-4301.
 13. Rotondi M, Castagna MG, Cappelli C, et  al. Obesity does not 
modify the risk of differentiated thyroid cancer in a cytological 
series of thyroid nodules. Eur Thyroid J. 2016;5(2):125-131.
 14. Tamez-Pérez  HE, Martínez  E, Quintanilla-Flores  DL, Tamez-
Peña AL, Gutiérrez-Hermosillo H, Díaz de León-González E. The 
rate of primary hypothyroidism in diabetic patients is greater 
than in the non-diabetic population. An observational study. Med 
Clin (Barc). 2012;138(11):475-477.
 15. Li H, Qian J. Association of diabetes mellitus with thyroid cancer 
risk: a meta-analysis of cohort studies. Medicine (Baltimore). 
2017;96(47):e8230.
 16. Yeo Y, Ma SH, Hwang Y, et al. Diabetes mellitus and risk of thy-
roid cancer: a meta-analysis. Plos One. 2014;9(6):e98135.
 17. Davey  Smith  G, Ebrahim  S. “Mendelian randomization”: can 
genetic epidemiology contribute to understanding environmental 
determinants of disease? Int J Epidemiol. 2003;32(1):1-22.
 18. Yengo L, Sidorenko  J, Kemper KE, et al.; GIANT Consortium. 
Meta-analysis of genome-wide association studies for height and 
body mass index in ∼700000 individuals of European ancestry. 
Hum Mol Genet. 2018;27(20):3641-3649.
 19. Collins  R. What makes UK Biobank special? Lancet. 
2012;379(9822):1173-1174.
 20. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access 
resource for identifying the causes of a wide range of complex 
diseases of middle and old age. Plos Med. 2015;12(3):e1001779.
 21. Welsh S, Peakman T, Sheard S, Almond R. Comparison of DNA 
quantification methodology used in the DNA extraction protocol 
for the UK Biobank cohort. BMC Genomics. 2017;18(1):26.
 22. Bycroft  C, Freeman  C, Petkova  D, et  al. The UK Biobank re-
source with deep phenotyping and genomic data. Nature. 
2018;562(7726):203-209.
 23. Tyrrell JS, Yaghootkar H, Freathy RM, Hattersley AT, Frayling TM. 
Parental diabetes and birthweight in 236 030 individuals in the 
UK biobank study. Int J Epidemiol. 2013;42(6):1714-1723.
 24. Locke  AE, Kahali  B, Berndt  SI, et  al.; LifeLines Cohort Study; 
ADIPOGen Consortium; AGEN-BMI Working Group; 
CARDIOGRAMplusC4D Consortium; CKDGen Consortium; 
GLGC; ICBP; MAGIC Investigators; MuTHER Consortium; 
MIGen Consortium; PAGE Consortium; ReproGen Consortium; 
GENIE Consortium; International Endogene Consortium. 
Genetic studies of body mass index yield new insights for obesity 
biology. Nature. 2015;518(7538):197-206.
 25. Pulit  SL, Stoneman  C, Morris  AP, et  al.; GIANT Consortium. 
Meta-analysis of genome-wide association studies for body fat 
distribution in 694 649 individuals of European ancestry. Hum 
Mol Genet. 2019;28(1):166-174.
 26. Mahajan  A, Taliun  D, Thurner  M, et  al. Fine-mapping type 
2 diabetes loci to single-variant resolution using high-density 
imputation and islet-specific epigenome maps. Nat Genet. 
2018;50(11):1505-1513.
 27. Yaghootkar H, Lotta LA, Tyrrell J, et al. Genetic evidence for a 
link between favorable adiposity and lower risk of type 2 diabetes, 
hypertension, and heart disease. Diabetes. 2016;65(8):2448-2460.
 28. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. 
Mendelian randomization: using genes as instruments 
for making causal inferences in epidemiology. Stat Med. 
2008;27(8):1133-1163.
 29. Loh  PR, Tucker  G, Bulik-Sullivan  BK, et  al. Efficient Bayesian 
mixed-model analysis increases association power in large co-
horts. Nat Genet. 2015;47(3):284-290.
 30. Bowden  J, Del  Greco  M  F, Minelli  C, Davey  Smith  G, 
Sheehan NA, Thompson JR. Assessing the suitability of summary 
data for two-sample Mendelian randomization analyses using 
MR-Egger regression: the role of the I2 statistic. Int J Epidemiol. 
2016;45(6):1961-1974.
 31. Bowden  J, Davey Smith G, Haycock PC, Burgess  S. Consistent 
estimation in mendelian randomization with some invalid in-
struments using a weighted median estimator. Genet Epidemiol. 
2016;40(4):304-314.
 32. Tang  Y, Yan  T, Wang  G, et  al. Correlation between insulin re-
sistance and thyroid nodule in type 2 diabetes mellitus. Int J 
Endocrinol. 2017;2017:1617458.
 33. Fry  A, Littlejohns  TJ, Sudlow  C, et  al. Comparison of 
sociodemographic and health-related characteristics of UK 
biobank participants with those of the general population. Am J 
Epidemiol. 2017;186(9):1026-1034.
 34. Dean DS, Gharib H. Epidemiology of thyroid nodules. Best Pract 
Res Clin Endocrinol Metab. 2008;22(6):901-911.
 35. Clavel-Chapelon  F, Guillas  G, Tondeur  L, Kernaleguen  C, 
Boutron-Ruault MC. Risk of differentiated thyroid cancer in re-
lation to adult weight, height and body shape over life: the French 
E3N cohort. Int J Cancer 2010;126(12):2984-2990.
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article/105/7/e2398/5835841 by guest on 19 O
ctober 2020
